Jackie Parkin

Jackie is the SVP and Therapeutic Head, leading clinical development of alvelestat for alpha-1 antitrypsin deficiency (AATD) lung disease and collaborations for studies in COVID-19 and Bronchiolitis Obliterans Syndrome (BOS). She is also responsible for acumapimod in AECOPD and leflutrozole in male hypogonadism.

Jackie has 20 years' experience in pharmaceutical discovery and development, previously serving as Vice President for Clinical Development at GlaxoSmithKline, leading in immuno-inflammatory and infectious diseases. Prior to GSK, Jackie was a Clinical Senior Lecturer in Immunology at St Bartholomew's and the Royal London Hospital, caring for patients with HIV infection. This experience fuelled her passion for potential research, and development to deliver medicines that can improve people’s lives.